Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Marwan Fakih, MD, City of Hope, reviews upfront molecular panel testing in metastatic gastrointestinal cancers. 
Holly Pederson, MD, Cleveland Clinic, discusses ancestrally unbiased polygenic breast cancer risk assessment, presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of potatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…
Stay in the know.
OncNet Newsletter